The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: An international model

Value in Health

Volumn 10, Issue 2, 2007, Pages 98-116

  Aballéa, Samuel ^a   Chancellor, Jeremy ^a,i   Martin, Monique ^a   Wutzler, Peter ^b   Carrat, Fabrice ^c   Gasparini, Roberto ^d   Toniolo Neto, Joao ^e   Drummond, Michael ^a,f   Weinstein, Milton ^g,h  

^a i3 Innovus   (United Kingdom)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c INSERM   (France)

^d UNIVERSITY OF GENOA   (Italy)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF YORK   (United Kingdom)

^g i3 Global   (Canada)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ NONE   (United Kingdom)

Author keywords

Cost effectiveness analysis; Influenza; Model; Vaccination; Vaccines

Indexed keywords

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG UPTAKE; FATALITY; FLU LIKE SYNDROME; FRANCE; GERMANY; HEALTH CARE POLICY; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFLUENZA VACCINATION; ITALY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; QUALITY OF LIFE; REIMBURSEMENT; SENSITIVITY ANALYSIS; SOCIETY;

EID: 33947577377     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00157.x     Document Type: Article

References (80)

1. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798-811.
2. Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997;87:1944-50.
3. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831-7.
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
5. Zimmerman RK. Lowering the age for routine influenza vaccination to 50 years: AAFP leads the nation in influenza vaccine policy. Am Family Physician 1999;60:2061-70.
6. Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1-34.
7. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21:1769-75.
8. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-93.
9. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003;21:2216-26.
10. Bridges CB, Thompson WW, Mettzer M, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284:1655-63.
11. Yassi A, Murdzak C, Cheang M, et al. Influenza immunization: knowledge, attitude and behaviour of health care workers. Can J Infect Control 1994;9:103-8.
12. Leighton L, Williams M, Aubery D, Parker SH. Sickness absence following a campaign of vaccination against influenza in the workplace. Occup Med (Lond) 1996;46:146-50.
13. Das Gupta R, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK. Pharmacoeconomics 2002;20:475-84.
14. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996;9 (Suppl. 3):S62-6.
15. Burckel E, Ashraf T, Sousa Filho JP, et al. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics 1999;16:563-76.
16. Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997;29:181-5.
17. Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost-effectiveness study on influenza prevention in Hong Kong. Health Pol 2001;56:215-34.
18. Office of Technology Assessment. Cost-Effectiveness of Influenza Vaccination. Washington, DC: Office of Technology Assessment, 1981.
19. Donaldson L, Mullally S, Smith J. Update on the Influenza and Pneumococcal Vaccination Programmes. Available from: http://www.dh.gov.uk/ assetRoot/04/08/73/40/04087340.pdf [Accessed September 22, 2004].
20. Nichol KL, Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res 2004;103:3-8.
21. Classification Committee of WONCA. ICHPPC-2-Defined: Inclusion Criteria for the Use of the Rubrics of the International Classification of Health Problems in Primary Care. New York: Oxford University Press Inc., 1983.
22. Uphoff H, Cohen JM, Fleming D, Noone A. Harmonisation of national influenza surveillance morbidity data from EISS: a simple index. Euro Surveill 2003;8:156-64.
23. Busschbach JJ, van, Weijnen T, Nieuwenhuizen M, et al. A comparison of EQ-5D time trade-off values obtained in Germany, The United Kingdom and Spain. In: Brooks R, Rabin R, de Charro FT, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective: Evidence from the Euroqol BIOMED Research Programme. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2003; pp. 143-6.
24. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
25. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2001;CD001269.
26. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997;39:408-14.
27. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-44.
28. Villari P, Manzoli L, Boccia A. Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine 2004;22:3475-86.
29. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993;270:1956-61.
30. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
31. Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000;17:187-95.
32. Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-87.
33. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7:1-182.
34. Szucs T, Auzanneau N, Bondarenko K, et al. Influenza vaccination coverage rates in five European countries during the winter of 2003-2004. Abstract of poster presented at Influenza Vaccines for the World Conference, Lisbon (Portugal), May 24-26, 2004.
35. CNAMTS. Data presented in Povoa de Varzim, September 2003.
36. Ensemble, évitons la grippe. Available from: http://grippe.ameli. fr/pro/index.html [Accessed September 22, 2004].
37. UNIFESP, University of São Paulo. Projeto de Vigilância Epidemiológica da Gripe (VigiGripe). 2005.
38. Tacken M, Braspenning J, Spreeuwenberg P, et al. Patient characteristics determine differences in the influenza vaccination rate more so than practice features. Prev Med 2002;35:401-6.
39. Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:834-42.
40. Centers for Disease Control and Prevention. Public health and aging: influenza vaccination coverage among adults aged ≥50 years and pneumococcal vaccination coverage among adults aged ≥65 years - United States, 2002. MMWR Morb Mortal Wkly Rep 2003;52:987-92.
41. Update on Influenza in Brazil. Available from: http://www.paho.org/ english/AD/DPC/CD/eid-eer-26-nov-2003.htm [Accessed October 5, 2004].
42. Goal is to Vaccinate 10.6 Million Senior Citizens Against Flu during National Campaign. Available from: http://www.radiobras.gov.br [Accessed July 8, 2004].
43. Briggs A. Probabilistic analysis of cost-effectiveness models [editorial]. Value Health 2005;8:1-2.
44. Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002;137:225-31.
45. Nichol KL, Goodman M. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. Vaccine 2002;20 (Suppl. 2):S21-4.
46. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53:1-40.
47. Colombo GL, Nicosia V, Lesma A, et al. A Cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti). PharmacoEcon Ital Res Artic 2001;3:71-80.
48. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004;CD001269.
49. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749-59.
50. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002;20:2562-78.
51. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005;165:274-80.
52. Bos JM, Beutels P, Annemans L, Postma MJ. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 2004;22:1171-9.
53. Iglesias CP, Drummond MF, Rovira J. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care 2005;21:1-14.
54. Dominguez Uga MA. Economic analysis of the vaccination strategies adopted in Brazil in 1982. Bull Pan Am Health Organ 1988;22:250-68.
55. Ferraz ML, de Oliveira PM, Figueiredo VM, et al. The optimization of the use of economic resources for vaccination against hepatitis B in professionals in the health area. Rev Soc Bras Med Trop 1995;28:393-403.
56. Oliveira PM, Silva AE, Kemp VL, et al. Comparison of three different schedules of vaccination against hepatitis B in health care workers. Vaccine 1995;13:791-4.
57. Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005;352:323-5.
58. Stohr K, Esveld M. Public health. Will vaccines be available for the next influenza pandemic? Science 2004;306:2195-6.
59. Postma MJ, Jansema P, van Genugten ML, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002;62:1013-24.
60. INSERM. Sentinel Network (France). Available from: http://www.sentiweb. org/ [Accessed May 30, 2006].
61. European Influenza Surveillance Scheme. Available from: http://www.eiss.org/index.cgi [Accessed May 30, 2006].
62. Sorveglianza Clinico-Epidemiologica. Available from: http://www.flu.iss. it/aggiornamenti.htm [Accessed May 30, 2006].
63. Irwin DE, Weatherby LB, Huang WY, et al. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001;1:8.
64. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999;281:901-7.
65. Health Unified System. Available from: http://tabnet.datasus.gov.br/ tabnet/tabnet.htm [Accessed April 15, 2004].
66. Prior G. Self-reported health. In: Prescott-Clarke P, Primatesta P, eds. Health Survey for England '96, Vol. 1: Findings. London: The Stationery Office, 1998.
67. Saliou P, Auzanneau N, Bondarenko K. Influenza vaccination coverage in France during the winter of 2002-2003. Influenza Vaccines for the World, (Abstract). Lisbon, Portugal: May 24-26, 2004.
68. Auvray L, Dumesnil S, Le Fur P. Santé, soins et protection sociale en 2000. Paris: CREDES, 2001.
69. Wezel H, Liebold R. Handkommentar BMÄ, E-GO und GOÄ. Sankt Augustin: Asgard-Verlag, 2003.
70. Tabela de Procedimentos dos Sistemas de Informações Ambulatorial e Hospitalar do Sistema Único de Saúde (SIA e SIH/SUS). 2004. Sistemas de Informações Ambulatorial e Hospitalar do Sistema Único de Saúde (SIA e SIH/SUS).
71. Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 2002;162:1842-8.
72. Sessa A, Costa B, Bamfi F, et al. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001;18:629-34.
73. Cole JA, Loughlin JE, Ajene AN, et al. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther 2002;24:1824-39.
74. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40.
75. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998;48:85-90.
76. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003;97 (Suppl. C):S43-50.
77. Lucioni C, Costa B, Sessa A. I costi dell'influenza in Italia. Farmeconomia E Percorsi Terapeutici 2001;2:11-8.
78. Paternoster A. Labour Costs Survey 2000: Eu member states and candidate countries. Statistics in Focus. Monograph/Luxembourg, Belgium: European Communities, 2003.
79. Fernandes R, Menezes-Filho N. Impactos dos encargos trabalhistas sobre o setor formal da economia. In: Chahad J, Fernandes R, eds. O Mercado de Trabalho no Brasil: Políticas, Resultados e Desafios. São Paulo: MTE/FIPE, 2002.
80. Gasparini R, Lucioni C, Lai P, et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 2002;20 (Suppl. 5):B50-4.